Drug discovery: A jump-start for electroceuticals
Author(s)
Famm, Kristoffer; Litt, Brian; Tracey, Kevin J.; Boyden, Edward Stuart; Slaoui, Moncef![Thumbnail](/bitstream/handle/1721.1/92374/Boyden_Drug%20discovery.pdf.jpg?sequence=4&isAllowed=y)
DownloadBoyden_Drug discovery.pdf (123.8Kb)
OPEN_ACCESS_POLICY
Open Access Policy
Creative Commons Attribution-Noncommercial-Share Alike
Terms of use
Metadata
Show full item recordAbstract
Imagine a day when electrical impulses are a mainstay of medical treatment. Your clinician will administer electroceuticals that target individual nerve fibres or specific brain circuits to treat an array of conditions. These will modulate the neural impulses that control the body, repair lost function and reinstate a healthy balance. They could coax insulin from islet cells, regulate food intake, and control inflammation. They may treat pressing major ailments such as hypertension, diabetes, obesity, heart failure, pulmonary and vascular disease. All this is within reach, we argue, if researchers from disparate disciplines in academia and industry work together. We herewith outline what needs to be done to bring about electroceuticals, and unveil a public-private research initiative and award that aim to catalyse the field.
Date issued
2013-04Department
Massachusetts Institute of Technology. Department of Biological Engineering; Massachusetts Institute of Technology. Department of Brain and Cognitive SciencesJournal
Nature
Publisher
Nature Publishing Group
Citation
Famm, Kristoffer, Brian Litt, Kevin J. Tracey, Edward S. Boyden, and Moncef Slaoui. “Drug Discovery: A Jump-Start for Electroceuticals.” Nature 496, no. 7444 (April 10, 2013): 159–161.
Version: Author's final manuscript
ISSN
0028-0836
1476-4687